These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 20159797)
21. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma. McCaffrey JA; Herr HW Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087 [TBL] [Abstract][Full Text] [Related]
22. [Evidence-based medicine for urological cancer chemotherapy]. Tsukamoto S; Miyanaga N; Kawai K; Akaza H Gan To Kagaku Ryoho; 2000 Feb; 27(2):183-91. PubMed ID: 10700888 [TBL] [Abstract][Full Text] [Related]
23. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma]. Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667 [TBL] [Abstract][Full Text] [Related]
24. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Soga N; Onishi T; Arima K; Sugimura Y Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750 [TBL] [Abstract][Full Text] [Related]
25. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study. Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830 [TBL] [Abstract][Full Text] [Related]
26. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer. Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636 [TBL] [Abstract][Full Text] [Related]
27. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Bellmunt J; Delgado FM; George C Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178 [TBL] [Abstract][Full Text] [Related]
28. Systemic chemotherapy of transitional cell carcinoma of the urothelium. Chun HG; Dorr FA Cancer Treat Res; 1989; 42():151-74. PubMed ID: 2577102 [No Abstract] [Full Text] [Related]
29. Lobaplatin in combination with methotrexate and vinblastine in patients with transitional cell carcinoma of the urinary tract--a pilot phase I/(II) study. Jung P; Bachmann P; Burk K; Jakse G Eur J Cancer; 1995 Oct; 31A(11):1891-2. PubMed ID: 8541125 [No Abstract] [Full Text] [Related]
30. A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract. Barrett JT; Orofiamma B; Khandekar JD; Carbone PP; Comis RL; Davis TE Cancer; 1989 Dec; 64(12):2445-7. PubMed ID: 2684384 [TBL] [Abstract][Full Text] [Related]
31. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? Sonpavde G; Galsky MD; Vogelzang NJ J Clin Oncol; 2010 Sep; 28(25):e441-2; author reply e443-4. PubMed ID: 20644092 [No Abstract] [Full Text] [Related]
32. Translational research to realize the full potential of novel agents--an opportunity for vinflunine? Yip AY; Ong EY; Chow LW Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S5-8. PubMed ID: 21957991 [TBL] [Abstract][Full Text] [Related]
33. [First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metastatic urothelial carcinoma (keynote 361-AB 54/16 of the AUO)]. Rexer H; Ohlmann CH; Retz M Urologe A; 2017 May; 56(5):659-661. PubMed ID: 28349185 [No Abstract] [Full Text] [Related]
34. Progress in treatment of advanced urothelial tract tumors. Yagoda A J Clin Oncol; 1985 Nov; 3(11):1448-50. PubMed ID: 3903061 [No Abstract] [Full Text] [Related]
35. The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation. Lewis R; Bagnall AM; King S; Woolacott N; Forbes C; Shirran L; Duffy S; Kleijnen J; ter Riet G; Riemsma R Health Technol Assess; 2002; 6(14):1-269. PubMed ID: 12583816 [No Abstract] [Full Text] [Related]
36. Durvalumab: First Global Approval. Syed YY Drugs; 2017 Aug; 77(12):1369-1376. PubMed ID: 28643244 [TBL] [Abstract][Full Text] [Related]
37. Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. Bamias A; Hegele A; Medioni J; Castellano D; Doni L; Passalacqua R; Zagouri F; Tzannis K; Hussain S; Ullen A Crit Rev Oncol Hematol; 2019 Aug; 140():80-87. PubMed ID: 31133463 [TBL] [Abstract][Full Text] [Related]
38. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma. Benjamin DJ; Lythgoe MP; Rezazadeh A BJU Int; 2023 Jun; 131(6):691-693. PubMed ID: 36877951 [No Abstract] [Full Text] [Related]